Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/oncotarget.16209 http://scihub22266oqcxt.onion/10.18632/oncotarget.16209 C5514898!5514898 !28415761     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28415761 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Oncotarget 2017 ; 8 (23 ): 37154-37163 Nephropedia Template TP {{tp|p=28415761 |t=2017. YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma |pdf=|usr=}}{{28415761 }} gab.com Text YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=28415761 #FOAvip The transcriptional co-activator Yes-associated protein (YAP) is essential for Hippo pathway-driven tumorigenesis in various cancers. However, the expression and function of YAP in neuroblastoma remains elusive. Here, we show that YAP was highly expressed in Neuroblastoma (NB) and expression levels correlated with advanced tumor staging. Knockdown of YAP significantly impaired neuroblastoma proliferation, tumorigenesis, and invasion in vitro. Injection of the YAP inhibitor, Peptide 17, dramatically prevented neuroblastoma subcutaneous tumor growth by efficiently downregulating YAP expression in tumors. Additionally, less proliferative and more apoptotic cells were found in the Peptide 17 treatment group. Furthermore, YAP inhibition significantly inhibited cisplatin-resistant neuroblastoma proliferation, tumorigenesis, and invasion in vitro. The combination of Peptide 17 with low-dose cisplatin efficiently impaired cisplatin-resistant NB subcutaneous tumor growth, being as effective as high-dose cisplatin. Notably, the combination therapy caused lesser liver toxicity in mice compared to the high-dose cisplatin treatment group. Collectively, this work identifies YAP as a novel regulator of neuroblastoma proliferation, tumorigenesis, and invasion and indicates that YAP is a potential therapeutic target for cisplatin-resistant neuroblastoma. Twit Text FOAVip YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=28415761 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28415761 #FOAvip English Wikipedia <ref>{{Cite pmid|28415761 }}</ref> YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma #MMPMID28415761 Yang C ; Tan J ; Zhu J ; Wang S ; Wei G Oncotarget 2017[Jun]; 8 (23 ): 37154-37163 PMID28415761 show ga The transcriptional co-activator Yes-associated protein (YAP) is essential for Hippo pathway-driven tumorigenesis in various cancers. However, the expression and function of YAP in neuroblastoma remains elusive. Here, we show that YAP was highly expressed in Neuroblastoma (NB) and expression levels correlated with advanced tumor staging. Knockdown of YAP significantly impaired neuroblastoma proliferation, tumorigenesis, and invasion in vitro. Injection of the YAP inhibitor, Peptide 17, dramatically prevented neuroblastoma subcutaneous tumor growth by efficiently downregulating YAP expression in tumors. Additionally, less proliferative and more apoptotic cells were found in the Peptide 17 treatment group. Furthermore, YAP inhibition significantly inhibited cisplatin-resistant neuroblastoma proliferation, tumorigenesis, and invasion in vitro. The combination of Peptide 17 with low-dose cisplatin efficiently impaired cisplatin-resistant NB subcutaneous tumor growth, being as effective as high-dose cisplatin. Notably, the combination therapy caused lesser liver toxicity in mice compared to the high-dose cisplatin treatment group. Collectively, this work identifies YAP as a novel regulator of neuroblastoma proliferation, tumorigenesis, and invasion and indicates that YAP is a potential therapeutic target for cisplatin-resistant neuroblastoma. |Adaptor Proteins, Signal Transducing/antagonists & inhibitors/genetics/*metabolism [MESH] |Animals [MESH] |Antineoplastic Agents/pharmacology [MESH] |Carcinogenesis/*drug effects/genetics/metabolism [MESH] |Cell Line, Tumor [MESH] |Cell Proliferation/drug effects/genetics [MESH] |Cell Survival/drug effects/genetics [MESH] |Cisplatin/*pharmacology [MESH] |Drug Resistance, Neoplasm [MESH] |Female [MESH] |Humans [MESH] |Mice, Inbred BALB C [MESH] |Mice, Nude [MESH] |Neuroblastoma/*drug therapy/genetics/metabolism [MESH] |Phosphoproteins/antagonists & inhibitors/genetics/*metabolism [MESH] |RNA Interference [MESH] |Transcription Factors [MESH] |Xenograft Model Antitumor Assays/methods [MESH]YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma (epmc).pdf DeepDyve Pubget Overpricing